MedPath

Boehringer Ingelheim USA Corporation

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

Phase 3
Completed
Conditions
Myocardial Infarction
Interventions
Drug: Full dose tenecteplase
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1606
Registration Number
NCT02181998

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 10 mg BI 1356 BS
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02183623

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
80
Registration Number
NCT02183545
Locations
πŸ‡°πŸ‡·

1333.3.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

πŸ‡°πŸ‡·

1333.3.82002 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of

Observational Study of Meloxicam in Any Labeled Indication

Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-10-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13039
Registration Number
NCT02182739

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 201335 NA soft gelatin capsule
Drug: [14C]-BI 201335 NA radiolabelled drug
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182349

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Phase 1
Completed
Conditions
Tumors
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
50
Registration Number
NCT02182206

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBF 1120 drinking solution
Drug: BIBF 1120 capsules charge 2
Drug: BIBF 1120 capsules charge 1
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
54
Registration Number
NCT02182193

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 10773 - single rising dose
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02182453

WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

Phase 3
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: WAL 801 CL Dry Syrup
Drug: WAL 801 CL Dry Syrup placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
162
Registration Number
NCT02182557

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Phase 3
Completed
Conditions
Myocardial Infarction
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
49
Registration Number
NCT02182011
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy